Meanwhile, studies have also shown that TKIs targeting c-Met combined with VEGF, RON inhibitors or specific tumor treatment strategies (such as anti-androgen therapy for PCa) can achieve better clinical efficacy. This evidence concerns the gene MST1R and neoplasm.